Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $1.00M.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.20M.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $1.00K.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K, a 0.00% change from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 0.00% change from fiscal 2021.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $100.00K, a 0.00% change from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.20M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $1.00K 10-K · filed 2026-03-30 | |||
| 2023-12-31 | $100.00K 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $0.00 derived: sum of 3 quarters · filed 2023-03-29 | $100.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $100.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $100.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $100.00K 10-K · filed 2023-03-29 | |||
| 2020-12-31 | $100.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |